81 results about "Tumor angiogenesis" patented technology

The invention discloses a wound-targeted intelligent nano-drug as well as a preparation method and application thereof. The wound-targeted intelligent nano-drug comprises a platelet membrane and drug-loaded nano-particles, wherein the platelet membrane coats the drug-loaded nano-particles; the drug-loaded nanoparticles contain a tumor angiogenesis inhibitor; the surface of the platelet membrane is connected with an anti-PDL1 antibody. The wound-targeted intelligent nano-drug can significantly improve the curative effect of a tumor angiogenesis inhibitor (sorafenib) and anti-PDL1 combined use, improve the biological distribution of the drug, reduce the toxic and side effects caused by the combined use of the sorafenib and anti-PDL1, greatly reduce the postoperative recurrence rate of early liver cancer, has a strong postoperative recurrence inhibition capability, and has a good application prospect. The biological safety is relatively excellent.

The invention discloses a tumor angiogenesis detection and analysis method based on multi-modal image fusion, and relates to the technical field of medical imaging, and the method comprises the steps: collecting multi-modal image data of a target tumor; performing feature extraction on the acquired multi-modal image data according to a neural network model; fusing the extracted features through a fusion network to obtain a comprehensive feature vector; analyzing the tumor angiogenesis state according to the comprehensive feature vector to obtain an analysis result; according to the analysis result, the angiogenesis state of the tumor is evaluated, and a report is generated. More comprehensive tumor angiogenesis information can be provided, and the accuracy of detection and analysis is improved. Through multi-modal image data fusion, the in-vivo tumor microenvironment can be simulated more truly. The method can be used as a preclinical research platform of anti-tumor and anti-tumor angiogenesis drugs, and provides support for drug screening and evaluation.

The invention relates to the technical field of biology, in particular to a method for preparing a mesenchymal stem cell exosome with a cancer cell inhibiting effect. According to the application, bioactive substances such as various growth factors, cell factors and exosomes which are rich in the stem cell conditioned culture medium are utilized, and the substances jointly act on cancer cells through various mechanisms such as inducing cell apoptosis, blocking a cell cycle and inhibiting tumor angiogenesis, so that a multi-layer anti-cancer effect is formed; especially, the addition of CBD further enriches or optimizes exosomes in the culture medium, the exosomes may carry more molecules with anticancer characteristics under the induction of CBD, the potential inhibition effect on cancer cells is significantly enhanced, and in addition, the stem cell conditioned culture medium as a treatment tool has a significant treatment effect on cancer cells. Especially, cannabidiol with relatively low cost is combined for treatment, a new thought is provided for developing a cancer treatment strategy with reasonable cost, and the method is expected to reduce the overall treatment cost, so that more patients are benefited.

The invention discloses a neurovascular tumor recognition system based on image recognition, and belongs to the technical field of neurovascular tumor image recognition, the neurovascular tumor recognition system comprises an image acquisition and processing module, a feature extraction and evaluation module and a result visualization module, the feature extraction and evaluation module comprises a basic recognition and evaluation unit and a combined hydrodynamics evaluation unit, the tumor malignant risk assessment system can comprehensively reflect tumor basic image features, tumor growth environment and metabolism requirements, integrates multi-dimensional information, accurately assesses tumor malignant risks, reflects dynamic changes of the tumor malignant risks along with time, and solves the problems that in the prior art, single feature assessment exists, blood flow information fusion is lacked, and the tumor malignant risk assessment efficiency is high. The defect of dynamic change in the aspect of tumor angiogenesis is not considered.

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The invention discloses an application of a Galectin-3 glycosylation inhibitor in preparation of an anti-esophageal cancer angiogenesis medicine, and belongs to the technical field of biological medicines. The invention particularly relates to application of a reagent for promoting mutagenesis of an O-GlcNAc modification site of Galectin-3 in preparation of a medicine for resisting tumor angiogenesis. The Galectin-3 is obviously higher in serum of an esophageal cancer patient than a healthy control, the glycosylation modification level of Galectin-3 in esophageal cancer cells is changed through molecular biology means such as construction of Galectin-3 specific plasmids and the like, it is found for the first time that interference on Galectin-3 glycosylation modification can obviously inhibit esophageal cancer cell angiogenesis mimicry, and therefore the Galectin-3 can be used for inhibiting esophageal cancer cell angiogenesis mimicry. The Galectin-3 glycosylated modified specific plasmid and other molecular biological means constructed by the invention can be applied to preparation, screening or treatment of esophageal cancer or inhibition of esophageal cancer angiogenesis, and a new treatment method is provided for intervention or treatment of esophageal cancer.

The invention provides a broad-spectrum combined medicine for treating colorectal cancer. The broad-spectrum combined medicine is prepared from the following components in parts by weight: 100 parts of purified water, 38 to 90 parts of tripterygium wilfordii alkaloid, 38 to 90 parts of tripterygium hypoglaucum alkaloid, 28 to 85 parts of chamaejasmine, 28 to 85 parts of gelsmium elegans alkaloid and 28 to 85 parts of xanthoxylin. The medicine is prepared from the following raw materials in parts by weight: 16 to 80 parts of ganoderan, 16 to 80 parts of pinellia ternate sitosterol, 16 to 80 parts of radix rehmanniae praeparata, 16 to 80 parts of astragaloside, 16 to 80 parts of oldenlandia diffusa alkaloid, 16 to 80 parts of sculellaria barbata alkaloid, 16 to 80 parts of tanshinone, 16 to 80 parts of carthamin, 16 to 80 parts of honeysuckle chlorogenic acid and 16 to 80 parts of pericarpium citri reticulatae flavone. By integrating anti-tumor components with multiple action mechanisms, tripterygium wilfordii alkaloid, tripterygium hypoglaucum alkaloid and the like, tumor cell proliferation can be directly inhibited, and apoptosis can be induced; tanshinone, emodin and the like can inhibit tumor angiogenesis; ganoderma lucidum polysaccharides, astragaloside and the like can activate the immune system of the body, enhance the activity of T cells and NK cells, and form double strikes of direct killing and immune surveillance.

This invention belongs to the pharmaceutical field, specifically relating to an anti-tumor angiogenesis drug potentiator, an anti-tumor drug composition, and its application. Firstly, this invention discovers that SHCBP1 inhibitors can enhance the therapeutic effect of anti-tumor angiogenesis drugs and can be used as potentiators for anti-tumor angiogenesis drugs. Secondly, when SHCBP1 inhibitors are used in combination with anti-tumor angiogenesis drugs, or in combination with anti-tumor angiogenesis drugs and PD-1 inhibitors, tumor angiogenesis can be normalized and its window period prolonged, significantly improving the efficacy of immunotherapy, anti-angiogenesis, and anti-tumor therapy, showing broad application prospects.

The invention discloses a specific interference polypeptide and application thereof. The amino acid sequence of the specific interference polypeptide disclosed by the invention is an amino acid sequence as shown in one of SEQ ID No.1 and SEQ ID No.1: NMEAQNTTEVYVK; sEQ ID No. 2: QNTTEVYVK is shown as SEQ ID No. 2. The specific interference polypeptide provided by the invention targets alpha v beta 3 / CD47-SIRP alpha for interaction, has no side effects of splitting erythrocytes and promoting tumor angiogenesis, and can be used for preparing medicines for treating tumors.

The present invention relates to the field of biomedicine and specifically relates to an anti-VEGF-anti-PD-L1 bispecific antibody, a pharmaceutical composition of same, and uses thereof. Specifically, the present invention relates to the bispecific antibody, which comprises: a VEGF-targeted first protein functional area and a PD-L1-targeted second protein functional area, wherein: the first protein functional area is an anti-VEGF antibody or an antigen-binding fragment thereof, or, the first protein functional area comprises a VEGF receptor or a fragment having a VEGF receptor function, and the second protein functional area is an anti-PD-L1 monoclonal antibody. The bispecific antibody of the present invention is capable of activating the immune system and blocking tumor angiogenesis at the same time, and provides great antitumor prospects.

The present invention relates to the field of biomedicine and specifically relates to an anti-VEGF-anti-PD-L1 bispecific antibody, a pharmaceutical composition of same, and uses thereof. Specifically, the present invention relates to the bispecific antibody, which comprises: a VEGF-targeted first protein functional area and a PD-L1-targeted second protein functional area, wherein: the first protein functional area is an anti-VEGF antibody or an antigen-binding fragment thereof, or, the first protein functional area comprises a VEGF receptor or a fragment having a VEGF receptor function, and the second protein functional area is an anti-PD-L1 monoclonal antibody. The bispecific antibody of the present invention is capable of activating the immune system and blocking tumor angiogenesis at the same time, and provides great antitumor prospects.

The invention provides an anti-VEGFR2 (vascular endothelial growth factor receptor 2) antibody preparation which comprises an anti-VEGFR2 antibody, a buffer solution, a protein protective agent and a surfactant, and the pH (potential of hydrogen) value of the antibody preparation is 5.0-6.7. The anti-VEGFR2 antibody preparation of the present invention can maintain the stability of the antibody in a liquid form. In addition, the invention also relates to application of the anti-VEGFR2 antibody preparation in preparation of drugs for preventing and / or treating diseases caused by tumor angiogenesis.

The invention discloses an application of an esterase response cationic polymer in preparation of an anti-tumor immunotherapy drug. The esterase response cationic polymer is an esterase response cationic polymer containing (p-phenolic ester group) benzyl amine or (p-phenolic ester group) benzyl ester. The compound can kill tumor cells, induce immunogen cell death (ICD), promote the tumor cells to release tumor-associated antigens, induce antigen-presenting cells to gather in tumors and present tumor antigens, activate killer T cells, inhibit tumor neovascularization, improve the tumor microenvironment, inhibit tumor cell apoptosis, inhibit tumor cell apoptosis, inhibit tumor cell apoptosis and inhibit tumor cell apoptosis after intratumor injection. Therefore, the organism obtains the anti-tumor immunity capability.

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

The invention relates to a construction method of a perfusion vascularized cervical cancer organoid chip, and relates to the technical field of biology. Comprising the following steps: S1, constructing a cervical cancer organ; s2, mixing the cervical cancer organ small cell cluster, the human umbilical vein endothelial cells and the human embryonic lung fibroblasts in proportion, and centrifugally gathering the mixed cells in a low-adsorption U-shaped plate to form a pre-vascularized cervical cancer organ; s3, re-suspending the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells in the fibrous protein hydrogel, transferring the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells into the organoid chip, and adding a vascularized cervical cancer organoid culture medium for culture, so that the endothelial cells form perfused blood vessels, and finally obtaining the perfused vascularized cervical cancer organoid chip. The prepared perfusion vascularized cervical cancer organoid can well solve the in-vitro vascularization problem of the organoid, simulates the in-vivo tumor angiogenesis process, is close to the in-vivo real tumor microenvironment, and provides technical support for exploration of cervical cancer disease mechanisms and related treatment.

The present application relates to the technical field of RPS4X, and particularly relates to siRNA targeting RPS4X gene, LAMB3-PI3K-AKT signal pathway inhibitor, ovarian cancer drug and application. The siRNA targets and interferes with RPS4X gene expression. The siRNA and the LAMB3-PI3K-AKT signal pathway inhibitor are used on in-vitro ovarian cancer cells and in-vivo ovarian cancer tissues, and both have the effect of inhibiting proliferation, migration and invasion. The various siRNAs targeting RPS4X gene and the LAMB3-PI3K-AKT signal pathway inhibitors provided in the embodiments have the effects of promoting apoptosis of ovarian cancer cells and tissues and inhibiting tumor angiogenesis, have obvious ovarian cancer prevention and treatment effects, and have the application prospect of developing as ovarian cancer drugs.

Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of the drug comprise the clostridium ghonii and the tumor angiogenesis inhibitor.

The present application provides a derivative with a repaglinide tetravalent platinum structure and a preparation method and use thereof, the compound with the repaglinide tetravalent platinum structure is shown as general formula (I), wherein, selected from cisplatin or oxaliplatin; L is hydroxyl or a series of repaglinide platinum (IV) compounds targeting p53 pathway described in the present application, which shows good anti-proliferation and anti-metastasis activity in vitro and in vivo. The severe DNA damage caused by platinum core can up-regulate the expression of p53, and repaglinide (RPG) can also effectively promote the secretion of p53 through the lumican / p53 / p21 pathway. The present application designs and synthesizes a series of repaglinide tetravalent platinum derivatives, which can start mitochondrial-mediated apoptosis through the Bcl-2 / Bax / caspase-3 pathway. Subsequently, with the up-regulation of p53, the compound can effectively activate pro-apoptotic autophagy, inhibit the epithelial-mesenchymal transition (EMT) process, and then inhibit tumor angiogenesis by inhibiting COX-2, MMP9 and VEGFA. The compound can also increase the number of CD3 + And CD8 + T cells in tumors by blocking immune checkpoint PD-L1, and stimulate anti-tumor immunity. The above multiple anti-tumor mechanisms synergistically inhibit the proliferation and metastasis of tumor cells.

The invention belongs to the technical field of medicines, and particularly relates to an application of oleanolic acid in tumor resistance, and the application of oleanolic acid in tumor resistance specifically comprises the following steps: inhibiting tumor cell proliferation and inducing apoptosis; tumor angiogenesis is inhibited; the drug resistance of tumor cells is reversed; the immune function is regulated, and the anti-tumor immunity is enhanced; tumor invasion and metastasis are inhibited; according to the method, supercritical CO2 extraction is adopted, recoverable CO2 is used as an extraction medium, and no toxic organic solvent such as chloroform is used in the whole process; a small amount of ethanol is used only in the links of resin activation and elution, and is recovered through vacuum concentration, so that the use amount is extremely small, the treatment is easy, and the environmental pollution caused by solvent leakage or residue is avoided from the source.

The invention discloses an apatinib-immune synergistic nano-drug based on bacterial source vesicles as well as a preparation method and application of the apatinib-immune synergistic nano-drug. The nano-drug is Apatinib-MVs, and the nano-drug takes a membrane vesicle secreted by parabacteroides coumarini as a carrier to entrap an anti-angiogenesis drug apatinib; in-vitro anti-tumor experiment results show that the nano-drug can exert an efficient anti-tumor effect through a dual synergistic mechanism of inhibiting tumor angiogenesis and activating anti-tumor immune response at the same time.

The invention provides a derivative with a repaglinide tetravalent platinum structure and a preparation method and application of the derivative, the compound with the repaglinide tetravalent platinum structure is shown in the general formula (I), # imgabs0 #, # imgabs1 # is selected from cis-platinum or oxaliplatin, # imgabs2 # is selected from iso-platinum or oxaliplatin, and # imgabs2 # is selected from iso-platinum or oxaliplatin. L is hydroxyl or # imgabs2. A series of repaglinide platinum (IV) compounds taking the p53 pathway as the target spot disclosed by the invention show good anti-proliferation and anti-metastasis activity in vitro and in vivo. The expression of p53 can be up-regulated due to serious DNA damage caused by platinum nucleus, and repaglinide (RPG) can also effectively promote the secretion of p53 through a lumican / p53 / p21 pathway. According to the invention, a series of repaglinide tetravalent platinum derivatives are designed and synthesized, and the compounds start mitochondrial mediated apoptosis through a Bcl-2 / Bax / caspase-3 pathway. Afterwards, along with up-regulation of p53, the compound can effectively activate apoptosis-promoting autophagy and inhibit an epithelial-mesenchymal transition (EMT) process, and further inhibit angiogenesis of tumors by inhibiting COX-2, MMP9 and VEGFA (vascular endothelial growth factor A). The compound can also increase the number of CD3 + and CD8 + T cells in tumors by blocking an immune checkpoint PD-L1 and stimulate anti-tumor immunity. The multiple anti-tumor mechanisms synergistically inhibit proliferation and metastasis of tumor cells.

The invention discloses a cytochalasin compound with an anti-tumor effect as well as a preparation method and application of the cytochalasin compound. The compound disclosed by the invention is derived from a fermentation product of a cynanchum chinense endophytic fungus Aspergilusizukae RD-16. The compound disclosed by the invention has the advantages that the compound can be used for preparing the cynanchum chinense endophytic fungus; the compound has remarkable cytotoxic activity to various tumor cells and almost has no toxicity to normal colonic epithelial cells. Meanwhile, the compound also has an effect of inhibiting angiogenesis. A Western Blot experiment result proves that the compound activates the expression of tumor cell autophagy related protein by inhibiting a PI3K-AKT-mTOR signal channel and induces tumor cells to generate autophagy; on the other hand, by inhibiting expression of angiogenesis related protein p-VEGFR2, tumor angiogenesis is blocked, and the anti-tumor effect is synergistically enhanced through multiple paths. The compound has potential application in preparation of novel anti-tumor drugs, and provides scientific basis for research and development of novel anti-tumor drugs.

The invention relates to an anti-cancer composition based on natural active ingredients and a medicine thereof, and belongs to the technical field of medicine compositions. The anticancer composition based on the natural active ingredients is prepared from the following components in percentage by mass: 1 to 10 percent of ginsenoside Rg3, 5 to 20 percent of dihydroquercetin, 20 to 40 percent of lucid ganoderma extract, 15 to 30 percent of astragalus extract and 15 to 30 percent of coix seed extract. In the anti-cancer composition based on the natural active ingredients, ginsenoside Rg3 has the effect of inhibiting tumor angiogenesis; the dihydroquercetin has remarkable antioxidant and anti-inflammatory activity; ganoderma lucidum polysaccharide can enhance the immune function of the body. Astragaloside has an immunoregulation effect; coix seed ester has the anti-tumor metastasis activity, the anti-cancer effect is remarkably enhanced through the synergistic effect of multiple components, toxic and side effects are low, the composition is suitable for long-term taking, and the product quality is stable.

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

An intelligent wound-targeting nano-drug and a preparation method therefor and the use thereof. The intelligent wound-targeting nano-drug contains a platelet membrane and drug-loading nanoparticles, wherein the drug-loading nanoparticles are coated with the platelet membrane, the drug-loading nanoparticles contain a tumor angiogenesis inhibitor, and the surface of the platelet membrane is linked with an anti-PDL1 antibody. The intelligent wound-targeting nano-drug can significantly improve the therapeutic effect of the tumor angiogenesis inhibitor (sorafenib) in combination with the anti-PDL1 antibody, can improve the biodistribution of the drugs, can reduce toxic side effects caused by the combined use of the two, and can greatly reduce the postoperative recurrence rate of early liver cancer. The intelligent wound-targeting nano-drug has a strong capability for inhibiting postoperative recurrence and a relatively good biological safety.

The invention relates to the technical field of preparations for treating thyroid cancer patients, in particular to application of an iodine-containing composition in preparation of products for treating thyroid cancer. At present, a specific guidance scheme about the optimal iodine intake does not exist for patients with differentiated thyroid cancer (DTC), especially patients with structural persistent lesions after surgery and / or radioiodine treatment. In China, although definite evidences are lacked, a large number of patients still select lifelong low-iodine diets and try to avoid iodine-induced relapse. The application of the invention overcomes prejudice and proves that low-iodine diet can promote biochemical progress of thyroid cancer on the contrary, and iodine-suitable diet can better help patients with differentiated thyroid cancer to recover, inhibit RYR1 gene expression and weaken tumor angiogenesis and cell migration ability, thereby inhibiting tumor progress.

The invention discloses ingenol methyl crotonate and application of a composition containing the ingenol methyl crotonate in preparation of medicines for treating tumors, and belongs to the field of biological medicines. The ingenol methyl crotonate can inhibit formation of vascular mimicry after treatment of tumor vascular inhibition drugs, and is combined with nimotuzumab and other tumor vascular inhibition drugs for use to inhibit drug resistance of the tumor vascular inhibition drugs and further inhibit recurrence and metastasis of nasopharyngeal carcinoma, so that the survival rate of nasopharyngeal carcinoma patients is increased, the prognosis of the nasopharyngeal carcinoma patients is improved, and the nasopharyngeal carcinoma patients are promoted. Important clinical significance and industrial popularization and application prospects are realized.

The invention relates to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine compound composition for adjuvant therapy of cancers and a preparation method thereof. Comprising the following traditional Chinese medicine components in parts by weight: 5-10 parts of scorpio, 10-20 parts of royal jelly freeze-dried powder, 5-15 parts of ginseng, 10-20 parts of rhizoma polygonati, 10-30 parts of astragalus membranaceus, 5-15 parts of dendrobium officinale, 10-20 parts of rehmannia, 5-15 parts of lucid ganoderma, 10-30 parts of oldenlandia diffusa, 10-20 parts of radix ophiopogonis, 5-15 parts of dogwood, 10-20 parts of codonopsis pilosula, 5-15 parts of liquorice, 0.1-0.5 part of selenium yeast, 5-15 parts of edible tulip, 10-20 parts of hawthorn, 5-15 parts of chrysanthemum and 10-30 parts of dandelion. And 3-10 parts of cinnamon. The scorpion, the pseudobulbus cremastrae seu pleiones and other components can directly inhibit tumor cell proliferation and induce apoptosis; the selenium yeast can scavenge free radicals and inhibit tumor angiogenesis. The royal jelly freeze-dried powder, the ginseng, the astragalus membranaceus, the lucid ganoderma and the like can activate immune cells, improve the immune monitoring ability of a body and relieve immunosuppression caused by radiotherapy and chemotherapy.

The application provides sulfated derivatives of fucosylated chondroitin sulfate oligosaccharides and application thereof, and belongs to the technical field of marine drugs. The structure of the sulfated derivatives of fucosylated chondroitin sulfate oligosaccharides is mainly a disaccharide repeating unit with GlcA and GalNAc connected through a beta-1,3 / beta-1,4 glycosidic bond as a main chain, and a fucose connected to the O-3 position of GlcA as a side chain; sulfation occurs at any 1-3 positions of C4 and / or C6 of the acetylglucosamine in the main chain, and C2,3,4 of the fucose in the side chain. Through in-vivo and in-vitro level verification, the application plays an anti-tumor metastasis role by significantly inhibiting the adhesion of tumors to endothelium, platelets and the like and tumor angiogenesis, so as to use S-dFCS as an active substance, prepare a medicine or a health product with the aid of a pharmaceutically acceptable carrier, and be capable of being used for preventing and treating tumors and diseases related to postoperative metastasis.

The invention belongs to the technical field of biological medicine, and relates to application of PARVA as a target spot in lung cancer prevention and treatment. Specifically, the invention provides application of PARVA in preparation of drugs for treating or preventing lung cancer and application of PARVA in reagents or kits for diagnosis or prognosis evaluation of lung cancer. The invention further provides a lung cancer treatment medicine or a lung cancer prevention medicine taking PARVA as a target spot and a kit which comprises a reagent for detecting PARVA mRNA or protein expression and is used for lung cancer diagnosis or lung cancer prognosis evaluation. The invention provides application of PARVA as a target spot in prevention and treatment of lung cancer, and lung cancer cell proliferation, invasion and metastasis and tumor angiogenesis are inhibited by regulating and controlling expression or functions of PARVA in lung cancer cells and tumor microenvironment, so that effective treatment, early diagnosis, recurrence prevention and prognosis evaluation of lung cancer are realized.